Target Audience and Goal Statement
This activity is intended for electrophysiologists, interventional cardiologists, cardiac surgeons, clinical cardiologists,
cardiology nurses and nurse practitioners, and other allied healthcare professionals.
The goal of this activity is to reinforce the need for risk stratification of patients undergoing revascularization so as
to determine the appropriate need for therapy to prevent sudden cardiac death.
Upon completion of this activity, participants will be able to:
- Examine the mortality risk and risk for sudden cardiac arrest after coronary revascularization
- Evaluate measures to prevent sudden cardiac death in patients with compromised left ventricular ejection fraction after surgical
and/or percutaneous revascularization
Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of
an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant
financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial
relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food
and Drug Administration, at first mention and where appropriate in the content.
Moderator(s)

-
Rahul N. Doshi, MD, FACC
Assistant Professor of Medicine, University of California, Irvine; Director, Electrophysiology, UC Irvine Healthcare, St.
Jude Medical Center, Fullerton, California
Disclosures
Disclosure: Rahul N. Doshi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: St. Jude Medical; Boston Scientific
Served as a speaker or a member of a speakers bureau for: St. Jude Medical; Boston Scientific
Dr Doshi does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Doshi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Panelist(s)

-
Mina K. Chung, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Staff Cardiologist,
Cardiac Electrophysiology and Pacing, The Robert and Suzanne Tomisch Department of Cardiovascular Medicine, Cleveland Clinic,
Cleveland, Ohio
Disclosures
Disclosure: Mina K. Chung, MD, has disclosed no relevant financial relationships.
Dr Chung does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Chung does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

-
David E Kandzari, MD
Director, Interventional Cardiology; Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia
Disclosures
Disclosure: David E. Kandzari, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic; Boston Scientific; Micell Technologies, Inc.
Received grants for clinical research from: Abbott Vascular; Boston Scientific; Medtronic, Inc.
Dr Kandzari does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Kandzari does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

-
Eric E. Roselli, MD
Staff Surgeon, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
Disclosures
Disclosure: Eric E. Roselli, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic, Inc.
Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.
Dr Roselli does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Roselli does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Editor(s)
Acute MI Steering Committee
-
Deepak L.Bhatt, MD, MPH
Chief of Cardiology, VA Boston Healthcare System; Senior Physician, Brigham and Women's Hospital; Professor of Medicine, Harvard
Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts
Disclosures
Disclosure: Deepak L. Bhatt, MD, MPH, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eisai Inc.; Ethicon,
Inc.; Medtronic, Inc.; Sanofi; The Medicines Company; Medtronic, Inc.
-
Ted E. Feldman, MD
Director, Cardiac Catheterization Laboratory, Evanston Hospital, Evanston, Illinois
Disclosures
Disclosure: Ted E. Feldman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Boston Scientific; Coherex Medical, Inc.; Edwards Lifesciences;
Intervalve; Daiichi Sankyo, Inc.; Lilly USA, LLC; W.L. Gore & Associates, Inc.
Served as a speaker or a member of a speakers bureau for: Boston Scientific
Received grants for clinical research from: Abbott Laboratories; Boston Scientific; Edwards Lifesciences; St. Jude Medical;
W.L. Gore & Associates, Inc.
-
Jagmeet P. Singh, MD, PhD
Associate Professor of Medicine, Harvard Medical School; Director, Cardiac Resynchronization Therapy Program and Holter and
Noninvasive Electrophysiology Laboratory, Massachusetts General Hospital, Boston, Massachusetts
Disclosures
Disclosure: Jagmeet P. Singh, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Boston Scientific; Medtronic, Inc.; St. Jude Medical; Sorin Group; CardioInsight
Technologies Inc.; Thoratec Corporation
Served as a speaker or a member of a speakers bureau for: BIOTRONIK; Boston Scientific; St. Jude Medical; Sorin Group
Received grants for clinical research from: BIOTRONIK; Boston Scientific; St. Jude Medical; Sorin Group; Medtronic, Inc.
CME Reviewer(s)
Nurse Planner

-
Laurie E. Scudder, DNP, NP
Nurse Planner, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing
and Allied Health, George Washington University, Washington, DC
Disclosures
Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.
Accreditation Statements
For Physicians
-
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
Medscape, LLC designates this enduring material for a maximum of 0.5
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Contact This Provider
For Nurses
-
Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission
on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.
Accredited status does not imply endorsement by Medscape, LLC or ANCC of any commercial products discussed in conjunction with the educational activity.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.